breast cancer
course of cancer
Maintrac-AUTO CTC-analyser
approved Maintrac-CTC assay
primary cancer patients
acceptance of Maintrac CTC assays
individual cancer type
success control of solid tumor cancer therapy Worldwide cancer
future cancer disease management
automated Maintrac AUTO analyser
overall CTC biomarker market
obvious relevance of cancer diseases
automatic system
initial therapy
maintenance therapy
art biomarker system
big market
health care system
clinical validation
market penetration
effectiveness
phase
better monitoring of disease progression
best business model
ineffective therapies
clinical symptoms
circulating tumor cells
liquid biopsy assay
established manual method
appropriate sales model
addition business opportunities
predictive real time monitoring
innovative products
expected revenue potential of US
high demand
important impact
oncology specialists
need
savings cost
efficiency
CTCs
response level
public authorities
early indicator
upscaling
reimbursement
families
prognosis
Automatization
leading causes of death
bn
regulatory requirements
relapse
selection of treatment
standardized state
Forecasts
series-production readiness
innovation project
patient suffering
economic implications
equivalence
New precision diagnostics
objectives